Tanya Simuni1, Liz Uribe2, Hyunkeun Ryan Cho2, Chelsea Caspell-Garcia2, Christopher S Coffey2, Andrew Siderowf3, John Q Trojanowski4, Leslie M Shaw4, John Seibyl5, Andrew Singleton6, Arthur W Toga7, Doug Galasko8, Tatiana Foroud9, Duygu Tosun10, Kathleen Poston11, Daniel Weintraub12, Brit Mollenhauer13, Caroline M Tanner10, Karl Kieburtz14, Lana M Chahine15, Alyssa Reimer16, Samantha J Hutten16, Susan Bressman17, Kenneth Marek5. 1. Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: tsimuni@nmff.org. 2. Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA. 3. Departments of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4. Departments of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5. Institute for Neurodegenerative Disorders, New Haven, CT, USA. 6. Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA. 7. Laboratory of Neuroimaging (LONI), University of Southern California, Los Angeles, CA, USA. 8. Department of Neurology, University of California, San Diego, CA, USA. 9. Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA. 10. Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. 11. Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. 12. Departments of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Departments of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 13. Department of Neurology, University Medical Center Goettingen, Goettingen, Germany; Paracelsus-Elena-Klinik, Kassel, Germany. 14. Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. 15. Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA. 16. The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA. 17. Icahn School of Medicine, Mount Sinai, New York, NY, USA.
Abstract
BACKGROUND: The Parkinson's Progression Markers Initiative (PPMI) is an ongoing observational, longitudinal cohort study of participants with Parkinson's disease, healthy controls, and carriers of the most common Parkinson's disease-related genetic mutations, which aims to define biomarkers of Parkinson's disease diagnosis and progression. All participants are assessed annually with a battery of motor and non-motor scales, 123-I Ioflupane dopamine transporter (DAT) imaging, and biological variables. We aimed to examine whether non-manifesting carriers of LRRK2 and GBA mutations have prodromal features of Parkinson's disease that correlate with reduced DAT binding. METHODS: This cross-sectional analysis is based on assessments done at enrolment in the subset of non-manifesting carriers of LRRK2 and GBA mutations enrolled into the PPMI study from 33 participating sites worldwide. The primary objective was to examine baseline clinical and DAT imaging characteristics in non-manifesting carriers with GBA and LRRK2 mutations compared with healthy controls. DAT deficit was defined as less than 65% of putamen striatal binding ratio expected for the individual's age. We used t tests, χ2 tests, and Fisher's exact tests to compare baseline demographics across groups. An inverse probability weighting method was applied to control for potential confounders such as age and sex. To account for multiple comparisons, we applied a family-wise error rate to each set of analyses. This study is registered with ClinicalTrials.gov, number NCT01141023. FINDINGS: Between Jan 1, 2014, and Jan 1, 2019, the study enrolled 208 LRRK2 (93% G2019S) and 184 GBA (96% N370S) non-manifesting carriers. Both groups were similar with respect to mean age, and about 60% were female. Of the 286 (73%) non-manifesting carriers that had DAT imaging results, 18 (11%) LRRK2 and four (3%) GBA non-manifesting carriers had a DAT deficit. Compared with healthy controls, both LRRK2 and GBA non-manifesting carriers had significantly increased mean scores on the Movement Disorders Society Unified Parkinson's Disease Rating Scale (total score 4·6 [SD 4·4] healthy controls vs 8·4 [7·3] LRRK2 vs 9·5 [9·2] GBA, p<0·0001 for both comparisons) and the Scale for Outcomes for PD - autonomic function (5·8 [3·7] vs 8·1 [5·9] and 8·4 [6·0], p<0·0001 for both comparisons). There was no difference in daytime sleepiness, anxiety, depression, impulsive-compulsive disorders, blood pressure, urate, and rapid eye movement (REM) behaviour disorder scores. Hyposmia was significantly more common only in LRRK2 non-manifesting carriers (69 [36%] of 194 healthy controls vs 114 [55%] of 208 LRRK2 non-manifesting carriers; p=0·0003). Finally, GBA but not LRRK2 non-manifesting carriers showed increased DAT striatal binding ratios compared with healthy controls in the caudate (healthy controls 2·98 [SD 0·63] vs GBA 3·26 [0·63]; p<0·0001), putamen (2·15 [0·56] vs 2·48 [0·52]; p<0·0001), and striatum (2·56 [0·57] vs 2·87 [0·55]; p<0·0001). INTERPRETATION: Our data show evidence of subtle motor and non-motor signs of Parkinson's disease in non-manifesting carriers compared with healthy controls that can precede DAT deficit. Longitudinal data will be essential to confirm these findings and define the trajectory and predictors for development of Parkinson's disease. FUNDING: Michael J Fox Foundation for Parkinson's Research.
BACKGROUND: The Parkinson's Progression Markers Initiative (PPMI) is an ongoing observational, longitudinal cohort study of participants with Parkinson's disease, healthy controls, and carriers of the most common Parkinson's disease-related genetic mutations, which aims to define biomarkers of Parkinson's disease diagnosis and progression. All participants are assessed annually with a battery of motor and non-motor scales, 123-I Ioflupanedopamine transporter (DAT) imaging, and biological variables. We aimed to examine whether non-manifesting carriers of LRRK2 and GBA mutations have prodromal features of Parkinson's disease that correlate with reduced DAT binding. METHODS: This cross-sectional analysis is based on assessments done at enrolment in the subset of non-manifesting carriers of LRRK2 and GBA mutations enrolled into the PPMI study from 33 participating sites worldwide. The primary objective was to examine baseline clinical and DAT imaging characteristics in non-manifesting carriers with GBA and LRRK2 mutations compared with healthy controls. DAT deficit was defined as less than 65% of putamen striatal binding ratio expected for the individual's age. We used t tests, χ2 tests, and Fisher's exact tests to compare baseline demographics across groups. An inverse probability weighting method was applied to control for potential confounders such as age and sex. To account for multiple comparisons, we applied a family-wise error rate to each set of analyses. This study is registered with ClinicalTrials.gov, number NCT01141023. FINDINGS: Between Jan 1, 2014, and Jan 1, 2019, the study enrolled 208 LRRK2 (93% G2019S) and 184 GBA (96% N370S) non-manifesting carriers. Both groups were similar with respect to mean age, and about 60% were female. Of the 286 (73%) non-manifesting carriers that had DAT imaging results, 18 (11%) LRRK2 and four (3%) GBA non-manifesting carriers had a DAT deficit. Compared with healthy controls, both LRRK2 and GBA non-manifesting carriers had significantly increased mean scores on the Movement Disorders Society Unified Parkinson's Disease Rating Scale (total score 4·6 [SD 4·4] healthy controls vs 8·4 [7·3] LRRK2 vs 9·5 [9·2] GBA, p<0·0001 for both comparisons) and the Scale for Outcomes for PD - autonomic function (5·8 [3·7] vs 8·1 [5·9] and 8·4 [6·0], p<0·0001 for both comparisons). There was no difference in daytime sleepiness, anxiety, depression, impulsive-compulsive disorders, blood pressure, urate, and rapid eye movement (REM) behaviour disorder scores. Hyposmia was significantly more common only in LRRK2 non-manifesting carriers (69 [36%] of 194 healthy controls vs 114 [55%] of 208 LRRK2 non-manifesting carriers; p=0·0003). Finally, GBA but not LRRK2 non-manifesting carriers showed increased DAT striatal binding ratios compared with healthy controls in the caudate (healthy controls 2·98 [SD 0·63] vs GBA 3·26 [0·63]; p<0·0001), putamen (2·15 [0·56] vs 2·48 [0·52]; p<0·0001), and striatum (2·56 [0·57] vs 2·87 [0·55]; p<0·0001). INTERPRETATION: Our data show evidence of subtle motor and non-motor signs of Parkinson's disease in non-manifesting carriers compared with healthy controls that can precede DAT deficit. Longitudinal data will be essential to confirm these findings and define the trajectory and predictors for development of Parkinson's disease. FUNDING: Michael J Fox Foundation for Parkinson's Research.
Authors: Nancy J Butcher; Connie Marras; Margarita Pondal; Pablo Rusjan; Erik Boot; Leigh Christopher; Gabriela M Repetto; Rosemarie Fritsch; Eva W C Chow; Mario Masellis; Antonio P Strafella; Anthony E Lang; Anne S Bassett Journal: Brain Date: 2017-05-01 Impact factor: 13.501
Authors: Alberto Bergareche; Maria Cruz Rodríguez-Oroz; Ainara Estanga; Ana Gorostidi; Adolfo López de Munain; Tamara Castillo-Triviño; Javier Ruiz-Martínez; Elisabet Mondragón; Carles Gaig; Francisco Lomeña; Cristina Sarasqueta; Eduardo Tolosa; José Félix Martí-Massó Journal: Mov Disord Date: 2015-12-21 Impact factor: 10.338
Authors: Daryl J Wile; Pankaj A Agarwal; Michael Schulzer; Edwin Mak; Katherine Dinelle; Elham Shahinfard; Nasim Vafai; Kazuko Hasegawa; Jing Zhang; Jessamyn McKenzie; Nicole Neilson; Audrey Strongosky; Ryan J Uitti; Mark Guttman; Cyrus P Zabetian; Yu-Shin Ding; Mike Adam; Jan Aasly; Zbigniew K Wszolek; Matthew Farrer; Vesna Sossi; A Jon Stoessl Journal: Lancet Neurol Date: 2017-03-20 Impact factor: 44.182
Authors: Cameron Miller-Patterson; Jesse Y Hsu; Lana M Chahine; James F Morley; Allison W Willis Journal: Clin Auton Res Date: 2022-09-03 Impact factor: 5.625
Authors: Tanya Simuni; Michael C Brumm; Liz Uribe; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; Roy N Alcalay; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Kelly Nudelman; Duygu Tosun-Turgut; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha Hutten; Susan Bressman; Kenneth Marek Journal: Mov Disord Date: 2020-02-19 Impact factor: 10.338
Authors: Daniela Berg; Per Borghammer; Seyed-Mohammad Fereshtehnejad; Sebastian Heinzel; Jacob Horsager; Eva Schaeffer; Ronald B Postuma Journal: Nat Rev Neurol Date: 2021-04-20 Impact factor: 42.937